Arcturus Therapeutics Holdings Inc.
ARCT
$10.53
$0.232.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -45.37% | -16.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -45.37% | -16.42% | |||
| Cost of Revenue | 11.87% | 793.88% | |||
| Gross Profit | -927.65% | -94.42% | |||
| SG&A Expenses | -6.75% | 7.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.16% | -26.17% | |||
| Operating Income | -211.02% | 49.18% | |||
| Income Before Tax | -321.47% | 59.00% | |||
| Income Tax Expenses | 98.16% | -44.67% | |||
| Earnings from Continuing Operations | -334.67% | 59.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -334.67% | 59.90% | |||
| EBIT | -211.02% | 49.18% | |||
| EBITDA | -231.55% | 51.40% | |||
| EPS Basic | -335.63% | 60.04% | |||
| Normalized Basic EPS | -322.57% | 59.16% | |||
| EPS Diluted | -336.50% | 60.04% | |||
| Normalized Diluted EPS | -322.57% | 59.16% | |||
| Average Basic Shares Outstanding | -0.23% | 0.35% | |||
| Average Diluted Shares Outstanding | -0.23% | 0.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||